Cardiovascular Needle - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cardiovascular needle market is projected to be USD 98.30 million in 2025, USD 104.33 million in 2026, and reach USD 149.17 million by 2031, growing at a CAGR of 7.41% from 2026 to 2031. This report is Segmented by Product Type (Round Bodied Needles, Cutting Needles), Usage (Single-Use, Multiple-Use), Application (Coronary Artery Bypass Graft Surgery, Open-Heart Surgery, and More), End-User (Hospitals, Ambulatory Surgical Centers, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Cardiovascular Needle Market Trends and Insights

Rising Global Cardiovascular Disease Burden

The cardiovascular needle market has a durable demand base because the global cardiovascular disease burden continues to expand in absolute terms. Global incident cases increased from 34.74 million in 1990 to 66.81 million in 2021, which represented a 92.3% rise over the period. This pattern matters because lower age standardized rates have not reduced the number of patients who still move into advanced care pathways and eventually require surgery. The cardiovascular needle market therefore remains tied not only to disease prevalence, but also to the expanding number of patients reaching severe multivessel, structural, or repeat cardiac interventions. Each open cardiac procedure requires multiple needles across anastomosis, tissue approximation, and closure steps, so case growth translates into recurring unit demand.

Shift Toward Single-Use Sterile Needles

The cardiovascular needle market is also being shaped by a stronger push toward sterile, traceable, single-use instruments in accredited surgical settings. The WHO guideline on bloodstream and other infections associated with intravascular catheter use reinforces strict sterile technique expectations for vascular procedures and related instrument handling. In practice, this raises the compliance floor for cardiac centers that want consistent documentation and lower infection risk across procedure flows. Even though multiple-use needles are growing faster, the single-use segment still benefits from hospital policies that favor known sharpness, known sterility status, and ready integration into preassembled procedure kits. That combination supports premium pricing when manufacturers can package the needle as part of a broader surgical workflow rather than as a stand-alone commodity.

Substitution By Transcatheter and Sutureless Cardiac Techniques

A major restraint on the cardiovascular needle market is the continued substitution of open surgical valve procedures by transcatheter and sutureless approaches. In Germany during 2024, transcatheter procedures represented 54.9% of all isolated heart valve procedures, which shows that the procedural mix has already shifted materially in a mature cardiac surgery system. The cardiovascular needle market will therefore see stronger growth in applications that remain difficult to convert to catheter-based treatment. Companies with heavy exposure to surgical valve lines face more pressure than companies with broader coverage across bypass, repair, and hybrid procedures.

Other drivers and restraints analyzed in the detailed report include:

• Growth in CABG and Open-Heart Procedure Volumes
• Expansion of Robotic and Minimally Invasive Cardiac Surgery
• Limited Differentiation in Mature Standard Needle Offerings

Segment Analysis

Round bodied needles held 52.16% of cardiovascular needle market share in 2025. Their position reflects the central role of atraumatic tissue passage in vascular anastomosis, where the surgeon needs clean penetration without cutting fragile vessel walls. In open cardiac repair, this geometry helps preserve graft and native vessel integrity during repeated passes, which is why it remains the preferred format in many high-acuity settings. Cutting needles still serve an important role in tougher tissue, especially where surgeons must pass through fibrous structures such as calcified annuli, pericardium, or closure tissue.

The cardiovascular needle market for round bodied needles is expected to expand at 7.86% CAGR through 2031, which suggests that the leading format is not losing momentum as procedure requirements become more specialized. Robotic and minimally invasive procedures strengthen this pattern because thinner profiles and stable tip behavior become more important when the surgeon works through instrument interfaces rather than by direct hand motion. In the cardiovascular needle market, that kind of documented handling improvement gives round bodied formats a better chance of defending premium pricing than standard commodity lines can achieve.

Single-use needles held 53.43% share in 2025, which kept them in the leading position within the cardiovascular needle market. Their scale is supported by infection control discipline, surgeon preference for factory calibrated sharpness, and the ease of documenting sterility across each procedure. Single-use products also fit naturally into prepacked procedure kits, which reduces setup time and gives suppliers more scope to bundle value rather than compete only on unit price. For private hospitals and large cardiac centers, those workflow advantages often matter as much as the needle itself.

Multiple-use needles are anticipated to be the fastest-growing usage segment at 8.13% CAGR through 2031, which shows that the cardiovascular needle market is not moving in one uniform direction. Growth in this segment reflects the cost logic of public and budget-sensitive systems that need to expand procedure volumes without matching every increase in demand with higher consumables spending. In those settings, controlled resterilization protocols make multiple-use formats economically attractive when hospitals can manage quality and handling standards internally. The cardiovascular needle market is becoming more segmented by care model and reimbursement setting than by simple product labeling alone.

Complete Report Scope:

• By Product Type
  • Round Bodied Needles
  • Cutting Needles
• By Usage
  • Single-Use
  • Multiple-Use
• By Application
  • Coronary Artery Bypass Graft Surgery
  • Open-Heart Surgery
  • Cardiac Valve Procedures
  • Heart Transplant
  • Other Cardiovascular Surgeries
• By End-User
  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiac Specialty Clinics
  • Other End-Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 47.25% of cardiovascular needle market share in 2025, which kept it as the largest regional block. The region benefits from mature reimbursement structures, high surgical intensity in complex cardiac cases, and strong procurement ties between hospital systems and established suppliers. The cardiovascular needle market in North America also favors premium lines because hospitals are more likely to value handling consistency, sterile packaging, and documented performance in workflow-sensitive procedures. Regulatory discipline and bundled purchasing behavior also make entry harder for smaller suppliers that lack broad portfolios or validation support.

Europe remained the second-largest region, with Germany, France, and the United Kingdom anchoring procedure demand. France also remained a meaningful cardiac surgery market, and the ESC Atlas reported CABG rates of 266 procedures per million people in 2024. At the same time, the cardiovascular needle market in Europe faces more pressure from transcatheter valve substitution and from the added regulatory overhead associated with EU MDR compliance.

Asia-Pacific is projected to be the fastest-growing region at 10.32% CAGR through 2031, which gives the cardiovascular needle market size its strongest expansion path outside mature Western systems. Growth in the region is supported by broader cardiac care modernization, rising procedure capacity, and the widening role of private and public providers in advanced surgery. Japan stands out for premium demand characteristics because precision instrumentation and quality expectations support higher value products even in a mature environment. The Middle East and Africa and South America add a second growth layer for the cardiovascular needle market, where improving cardiac center capability creates room for both volume expansion and higher per-case product value.

List of Companies Covered in this Report:

• B. Braun
• Barber of Sheffield Ltd.
• Beckton Dickinson
• Boston Scientific
• Cardinal Health
• Cook Group
• CP Medical, Inc.
• Ethicon
• FSSB Surgical Needles GmbH
• KLS Martin Group
• MANI, Inc.
• Medtronic
• Merit Medical Systems
• Quality Needles Pvt. Ltd.
• Scanlan International
• Sklar Surgical Instruments
• Smiths Group
• Surtex Instruments Ltd.
• Symmetry Surgical
• Teleflex
• Terumo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support